Synergistic induction of the Fas (CD95) ligand promoter by Max and NFκB in human non-small lung cancer cells

Experimental Cell Research

Volumn 299, Issue 1, 2004, Pages 227-235

  Wiener, Zoltan ^a,b   Ontsouka, Edgar C ^a   Jakob, Sabine ^a   Torgler, Ralph ^a   Falus, Andras ^b,c   Mueller, Christoph ^a   Brunner, Thomas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Apoptosis; Signaling; Transcription; Tumor cells; Tumor necrosis factor family

Indexed keywords

DOXORUBICIN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAX PROTEIN; MYC PROTEIN; PHORBOL ESTER;

ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OBSERVATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; STRESS; TUMOR ESCAPE;

EID: 4043098344     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.05.031     Document Type: Article

References (51)

1. Amati B., Alevizopoulos K., Vlach J. Myc and the cell cycle. Front. Biosci. 3:1998;D250-D268
2. Schmidt E.V. The role of c-myc in cellular growth control. Oncogene. 18:1999;2988-2996
3. Boxer L.M., Dang C.V. Translocations involving c-myc and c-myc function. Oncogene. 20:2001;5595-5610
4. Facchini L.M., Penn L.Z. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 12:1998;633-651
5. Davis A.C., Wims M., Spotts G.D., Hann S.R., Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 7:1993;671-682
6. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128
7. Pelengaris S., Kahn M., Evan G. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:2002;321-334
8. Hueber A.O., Zornig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309
9. Brunner T., Kasibhatla S., Pinkoski M.J., Frutschi C., Yoo N.J., Echeverri F., Mahboubi A., Green D.R. Expression of Fas ligand in activated T cells is regulated by c-Myc. J. Biol. Chem. 275:2000;9767-9772
10. Wang R., Brunner T., Zhang L., Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene. 17:1998;1503-1508
11. Genestier L., Kasibhatla S., Brunner T., Green D.R. Transforming growth factor beta1 inhibits fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc [In Process Citation]. J. Exp. Med. 189:1999;231-239
12. Kasibhatla S., Beere H.M., Brunner T., Echeverri F., Green D.R. A 'non-canonical' DNA-binding element mediates the response of the fas-ligand promoter to c-Myc. Curr. Biol. 10:2000;1205-1208
13. Walker P.R., Saas P., Dietrich P.Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10:1998;564-572
14. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012
15. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today. 20:1999;46-52
16. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366
17. Cefai D., Schwaninger R., Balli M., Brunner T., Gimmi C.D. Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy. Cell Death Differ. 8:2001;687-695
18. Broers J.L., Viallet J., Jensen S.M., Pass H., Travis W.D., Minna J.D., Linnoila R.I. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am. J. Respir. Cell Mol. Biol. 9:1993;33-43
19. Ozkara H.A., Ozkara S., Topcu S., Criss W.E. Amplification of the c-myc oncogene in non-small cell lung cancer. Tumori. 85:1999;508-511
20. Johnson B.E., Brennan J.F., Ihde D.C., Gazdar A.F. Myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer. J. Natl. Cancer Inst. Monographs. 1992;39-43
21. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., Green D.R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol. Cell. 1:1998;543-551
22. Westwick J.K., Weitzel C., Minden A., Karin M., Brenner D.A. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J. Biol. Chem. 269:1994;26396-26401
23. Baud V., Liu Z.G., Bennett B., Suzuki N., Xia Y., Karin M. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino terminal effector domain. Genes Dev. 13:1999;1297-1308
24. Martin S.J., Reutelingsperger C.P., McGahon A.J., Rader J.A., van Schie R.C., LaFace D.M., Green D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1995;1545-1556
25. Brunner T., Mogil R.J., La Face D., Yoo N.J., Mahboubi A., Echeverri F., Martin S.J., Force W.R., Lynch D.H., Ware C.F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441-444
26. Brunner T., Yoo N.J., La Face D., Ware C.F., Green D.R. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int. Immunol. 8:1996;1017-1026
27. Amati B., Brooks M.W., Levy N., Littlewood T.D., Evan G.I., Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 72:1993;233-245
28. Harwood F.G., Kasibhatla S., Petak I., Vernes R., Green D.R., Houghton J.A. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J. Biol. Chem. 275:2000;10023-10029
29. Steffan N.M., Bren G.D., Frantz B., Tocci M.J., O'Neill E.A., Paya C.V. Regulation of IkB alpha phosphorylation by PKC- and Ca(2+)-dependent signal transduction pathways. J. Immunol. 155:1995;4685-4691
30. Lavon I., Pikarsky E., Gutkovich E., Goldberg I., Bar J., Oren M., Ben-Neriah Y. Nuclear factor-kappaB protects the liver against genotoxic stress and functions independently of p53. Cancer Res. 63:2003;25-30
31. Kavurma M.M., Khachigian L.M. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ. 10:2003;36-44
32. Grisham M.B., Palombella V.J., Elliott P.J., Conner E.M., Brand S., Wong H.L., Pien C., Mazzola L.M., Destree A., Parent L., Adams J. Inhibition of NF-kappa B activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol. 300:1999;345-363
33. Kasibhatla S., Genestier L., Green D.R. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J. Biol. Chem. 274:1999;987-992
34. Xia Y., Makris C., Su B., Li E., Yang J., Nemerow G.R., Karin M. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5243-5248
35. Faris M., Kokot N., Latinis K., Kasibhatla S., Green D.R., Koretzky G.A., Nel A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol. 160:1998;134-144
36. Pinkoski M.J., Green D.R. Fas ligand, death gene. Cell Death Differ. 6:1999;1174-1181
37. Pinkoski M.J., Brunner T., Green D.R., Lin T. Fas and Fas ligand in gut and liver. Am. J. Physiol.: Gasterointest. Liver Physiol. 278:2000;G354-G366
38. Brunner T., Wasem C., Torgler R., Cima I., Jakob S., Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin. Immunol. 15:2003;167-176
39. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:1998;5669-5675
40. Chen J.J., Sun Y., Nabel G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1998;1714-1717
41. Seino K., Kayagaki N., Okumura K., Yagita H. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:1997;165-170
42. Restifo N.P. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6:2000;493-495
43. O'Connell J., Houston A., Bennett M.W., O'Sullivan G.C., Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7:2001;271-274
44. Gugger M., Burckhardt E., Kappeler A., Hirsiger H., Laissue J.A., Mazzucchelli L. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J. Pathol. 196:2002;408-415
45. Grandori C., Cowley S.M., James L.P., Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16:2000;653-699
46. Baudino T.A., Cleveland J.L. The Max network gone mad. Mol. Cell. Biol. 21:2001;691-702
47. Hurlin P.J., Steingrimsson E., Copeland N.G., Jenkins N.A., Eisenman R.N. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif. EMBO J. 18:1999;7019-7028
48. Canelles M., Delgado M.D., Hyland K.M., Lerga A., Richard C., Dang C.V., Leon J. Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene. 14:1997;1315-1327
49. Lindeman G.J., Harris A.W., Bath M.L., Eisenman R.N., Adams J.M. Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. Oncogene. 10:1995;1013-1017
50. Friesen C., Herr I., Krammer P.H., Debatin K.-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:1996;574-577
51. Vuong H., Patterson T., Shapiro P., Kalvakolanu D.V., Wu R., Ma W.Y., Dong Z., Kleeberger S.R., Reddy S.P. Phorbol ester-induced expression of airway squamous cell differentiation marker, SPRR1B, is regulated by protein kinase Cdelta/Ras/MEKK1/MKK1-dependent/AP-1 signal transduction pathway. J. Biol. Chem. 275:2000;32250-32259